Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3
+
Regulatory T Cells (Tregs) in Human Cancers-Response
Clin Cancer Res
.
2019 Jun 1;25(11):3469-3470.
doi: 10.1158/1078-0432.CCR-19-0402.
Authors
Anu Sharma
#
1
,
Sumit K Subudhi
#
1
,
Jorge Blando
2
,
Luis Vence
2
,
Jennifer Wargo
3
,
James P Allison
2
,
Antoni Ribas
4
,
Padmanee Sharma
5
2
Affiliations
1
Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
2
Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
3
Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
4
Department of Hematology and Oncology, University of California Los Angeles, Los Angeles, California.
5
Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. PadSharma@mdanderson.org.
#
Contributed equally.
PMID:
31160495
PMCID:
PMC6662573
DOI:
10.1158/1078-0432.CCR-19-0402
No abstract available
Publication types
Letter
Comment
MeSH terms
CTLA-4 Antigen
Forkhead Transcription Factors
Humans
Immunotherapy
Neoplasms*
T-Lymphocytes, Regulatory*
Substances
CTLA-4 Antigen
FOXP3 protein, human
Forkhead Transcription Factors
Grants and funding
P30 CA016672/CA/NCI NIH HHS/United States
R35 CA197633/CA/NCI NIH HHS/United States